• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq Gets FDA Approval

    AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq Gets FDA Approval

  2. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Mallinckrodt Public Limited Company To Contact Brower Piven Before The Lead Plaintiff ...

    INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Mallinckrodt Public Limited Company To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

  3. Big Chinese Deals Stall on Capital-Outflows Clampdown

    Big Chinese Deals Stall on Capital-Outflows Clampdown

  4. Tighter Cash Controls Curb China's Overseas Deal Spree -- WSJ

    Tighter Cash Controls Curb China's Overseas Deal Spree -- WSJ

  5. UPDATE: Gold is smelling a rat in this 'animal spirits' market -- this is how

    UPDATE: Gold is smelling a rat in this 'animal spirits' market -- this is how

  6. UPDATE: Gold investors smell a rat in this 'animal spirits' market -- this is why

    UPDATE: Gold investors smell a rat in this 'animal spirits' market -- this is why

  7. UPDATE: Gold is smelling a rat in this 'animal spirits' market -- this is how

    UPDATE: Gold is smelling a rat in this 'animal spirits' market -- this is how

  8. Potassium Voltage Gated Channel Subfamily KQT Member 2 Pipeline Review, H2 2016 - Research and Markets

    Potassium Voltage Gated Channel Subfamily KQT Member 2 Pipeline Review, H2 2016 - Research and Markets

  9. Morganti Legal: Shareholder Investigation of BT Group plc

    Morganti Legal: Shareholder Investigation of BT Group plc

  10. The Top- and Bottom-Performing U.S. Equity Funds From the First Half

    I look at the highlights and lowlights in equityland.

12345

©2017 Morningstar Advisor. All right reserved.